In anti-GBM disease, anti-peroxidasin antibodies may contribute to pathogenesis by inhibiting sulfilimine cross-linking, revealing pathogenic epitopes and leading to the development or binding of anti-GBM antibodies. This evidence concerns the gene PXDN and glioblastoma.